Skip to main content

Integra LifeSciences Holdings Corporation (IART)

NASDAQ: IART · Delayed Price · USD
69.29 -0.34 (-0.49%)
Sep 20, 2021 4:00 PM EDT - Market closed
Market Cap5.86B
Revenue (ttm)1.51B
Net Income (ttm)205.54M
Shares Out84.69M
EPS (ttm)2.41
PE Ratio28.70
Forward PE20.16
Dividendn/a
Ex-Dividend Daten/a
Volume384,166
Open68.66
Previous Close69.63
Day's Range68.20 - 69.78
52-Week Range42.12 - 77.40
Beta1.24
AnalystsBuy
Price Target77.73 (+12.2%)
Est. Earnings DateOct 27, 2021

About IART

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. It operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, hydrocephalus management systems, intracranial monitoring equipment, and cranial...

IndustryHealth Care Equipment & Supplies
IPO DateAug 16, 1995
CEOPeter Arduini
Employees3,700
Stock ExchangeNASDAQ
Ticker SymbolIART
Full Company Profile

Financial Performance

In 2020, IART's revenue was $1.37 billion, a decrease of -9.60% compared to the previous year's $1.52 billion. Earnings were $133.89 million, an increase of 166.71%.

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for IART stock is "Buy." The 12-month stock price forecast is 77.73, which is an increase of 12.18% from the latest price.

Price Target
$77.73
(12.18% upside)
Analyst Consensus: Buy

News

Integra LifeSciences Announces Participation in Upcoming Investor Conferences

PRINCETON, N.J., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that it is participating in the...

2 weeks ago - GlobeNewsWire

Integra (IART) Up 1.5% Since Last Earnings Report: Can It Continue?

Integra (IART) reported earnings 30 days ago. What's next for the stock?

3 weeks ago - Zacks Investment Research

Here's Why You Should Retain Integra (IART) Stock for Now

Solid performance across the CSS and Tissue Technologies segments is driving the top line for Integra (IART).

3 weeks ago - Zacks Investment Research

Integra LifeSciences (IART) is a Top-Ranked Momentum Stock: Should You Buy?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

1 month ago - Zacks Investment Research

Integra (IART) Q2 Earnings Top Estimates, 2021 Guidance Up

Integra (IART) reports better-than-expected revenues with strong segmental performance driving the top line in second-quarter 2021.

1 month ago - Zacks Investment Research

Integra's Update On FY21 Acell Revenues To Weigh On Stock, Piper Sandler Says

Piper Sandler has raised the price target on Integra LifeSciences Holding Corporation (NASDAQ:IART) to $72 from $70 and reiterated a Neutral rating following the Q2 beat.  The company posted Q2 EPS of $...

1 month ago - Benzinga

Integra LifeSciences (IART) Tops Q2 Earnings and Revenue Estimates

Integra (IART) delivered earnings and revenue surprises of 17.91% and 3.69%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Recap: Integra Lifesciences Q2 Earnings

Shares of Integra Lifesciences (NASDAQ:IART) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share increased 139.39% over the past year to $0.79, which beat the esti...

1 month ago - Benzinga

Integra LifeSciences Reports Second Quarter 2021 Financial Results

Raises Full-Year 2021 Guidance Raises Full-Year 2021 Guidance

1 month ago - GlobeNewsWire

Medical Device Stocks' Earnings on Jul 28: TMO, ALGN & More

The sector's Q2 results are likely to reflect solid earnings and revenue growth on strong base business recovery.

Other symbols:ABTALGNDGXHOLXTMO
1 month ago - Zacks Investment Research

Integra LifeSciences (IART) Earnings Expected to Grow: Should You Buy?

Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Integra (IART) Releases Favorable PriMatrix Clinical Outcome

Integra's (IART) PriMatrix study data validates that one application of PriMatrix is needed to address hard-to-heal diabetic foot ulcers.

2 months ago - Zacks Investment Research

Integra LifeSciences Announces Positive Clinical Outcomes for PriMatrix® Dermal Repair Scaffold for the Management of...

Data Shows a Single Application of PriMatrix Closed More Wounds Than Standard of Care Alone Data Shows a Single Application of PriMatrix Closed More Wounds Than Standard of Care Alone

2 months ago - GlobeNewsWire

Integra's (IART) SurgiMend Gets Innovative Technology Contract

Integra's (IART) SurgiMend Collagen Matrix is recognized as a product that can potentially bring improvement to the health care industry.

2 months ago - Zacks Investment Research

Integra LifeSciences Receives Innovative Technology Contract from Vizient for SurgiMend® Collagen Matrix for Soft Tis...

Contract awarded for products that bring improvement to healthcare industry Contract awarded for products that bring improvement to healthcare industry

2 months ago - GlobeNewsWire

Integra LifeSciences to Host Second Quarter 2021 Financial Results Conference Call on July 28, 2021

PRINCETON, N.J., July 08, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release second quarter 2021 financial resul...

2 months ago - GlobeNewsWire

Integra LifeSciences Announces CEO Succession Plan

Peter Arduini to serve as President and CEO through the end of 2021 Candidate search launched to identify successor Peter Arduini to serve as President and CEO through the end of 2021 Candidate search l...

2 months ago - GlobeNewsWire

Integra (IART) Tissue Technologies Rebounds Amid Supply Woe

Integra's (IART) CSS segment too reflects a gradual recovery in procedure-based market as well as an improvement in hospital capital spending during the first quarter.

3 months ago - Zacks Investment Research

Integra (IART) Down 8.1% Since Last Earnings Report: Can It Rebound?

Integra (IART) reported earnings 30 days ago. What's next for the stock?

3 months ago - Zacks Investment Research

Integra LifeSciences Hosts Virtual Investor Day

PRINCETON, N.J., May 20, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will host an Investor Day meeting from 8:30 a.m. ...

4 months ago - GlobeNewsWire

Integra LifeSciences to Host Virtual Investor Day on May 20, 2021

PRINCETON, N.J., May 07, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will host an Investor Day meeting from 8:30 a.m. ...

4 months ago - GlobeNewsWire

Integra (IART) Q1 Earnings Beat Estimates, Gross Margin Down

Integra's (IART) first-quarter revenues improved year over year on organic growth across Codman Specialty Surgical and Tissue Technologies segments.

4 months ago - Zacks Investment Research

Integra (IART) Hits Fresh High: Is There Still Room to Run?

Integra (IART) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

4 months ago - Zacks Investment Research

Integra LifeSciences (IART) Q1 Earnings and Revenues Top Estimates

Integra (IART) delivered earnings and revenue surprises of 23.21% and 2.92%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Integra Lifesciences: Q1 Earnings Insights

Shares of Integra Lifesciences (NASDAQ:IART) rose 1.5% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 43.75% over the past year to $0.69, whi...

4 months ago - Benzinga